Elena Tarroja – National Institute of Health and Medical Research (INSERM), France

Bisphenol data from Europe – results and policy implications – 27 April – 2 pm CEST

Bisphenol A, the most widely used bisphenol, is ubiquitous in the environment, with the vast majority of population across Europe likely to be exposed at least low levels. There is a concern that exposure to BPA and to other bisphenol compounds (like BPS and BPF) used as replacements, could be linked to a variety of health outcomes in humans and in the environment. BPA has been classified as endocrine disruptor.

In this presentation, we will walk you through the scientific outcomes of HBM4EU to answer the main policy questions on bisphenols, relevant to risk assessment and regulatory decision-making. It will cover main results on the harmonized Human Biomonitoring data across Europe that have been produced and the development of new effect markers linking BPA to health effects. We will also present Human Biomonitoring Guidance Values (HBM-GVs) derived using PBPK modelling for BPA and BPS, as well as Adverse Outcome Pathways studies on BPS and BPF linking to health effects.


Elena Tarroja Aulina is a Scientific Project Manager at INSERM unit T3S – “Toxicology, Therapeutic Targets, cellular Signaling and Biomarkers”, where she is engaged in the EU project Human Biomonitoring for Europe (HBM4EU). Over the past 5 years, she has been involved in the coordination of the French National Hub, the activities within the Exposure and Health Pillar, the sustainability of the programme and the work on Bisphenols. Before joining INSERM, she was involved in promoting technological cooperation with Catalan research centres in France. Biologist by the University of Barcelona, she worked as a microbiologist for several companies and research institutes in Spain and Belgium, mainly in the fields of health and environment.



The HBM4EU project was launched in 2016 with the aim of improving the collective understanding of human exposure to hazardous chemicals and developing HBM as an exposure assessment method. The project had €74m in funding and jointly implemented by 120 partners from 28 participating countries – 24 EU member states plus Norway, Switzerland, Iceland and Israel and the European Environment Agency. One of its aims was to ensure the sustainability of HBM in the EU beyond 2021. The project ended in June 2022. The website will not be updated any longer, except the page on peer reviewed publications, but will be online until 2032.